Discovering depression in medical patients: Reasonable expectations

Annals of Internal Medicine

Volumn 126, Issue 6, 1997, Pages 463-465

  Coley, Christopher M ^b   Barry, Michael J ^a   Fleming, Craig ^c   Fahs, Marianne C ^d   Mulley, Albert G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Health Outcomes Associates   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC DISEASE; DEMENTIA; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; EDITORIAL; HUMAN; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; STROKE;

EID: 15644379892     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-6-199703150-00008     Document Type: Editorial

References (74)

1. Coley CM, Barry MJ, Fleming C, Mulley AG. Early detection of prostate cancer. I. Prior probability and effectiveness of tests. Ann Intern Med. 1997;126:394-406.
2. Barry MJ, Fleming C, Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? III. Management strategies and outcomes. Urology. 1995;46:277-89.
3. Garnick MB. Prostate cancer: screening, diagnosis, and management Ann Intern Med. 1993;118:804-18.
4. Mettlin C, Jones GW, Murphy GP. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin. 1993;43:83-91.
5. Whitmore WF Jr, Warner JA, Thompson IM Jr. Expectant management of localized prostatic cancer. Cancer. 1991;67:1091-6.
6. Jones GW. Prospective, conservative management of localized prostate cancer. Cancer. 1992;70(Suppl 1):307-10.
7. Moskovitz B, Nitecki S, Richter Levin D. Cancer of the prostate: is there a need for aggressive treatment? Urol Int. 1987;42:49-52.
8. George NJ. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. 1988;1:494-7.
9. Adolfsson J, Carstensen J. Natural course of clinically localized prostate adenocarcinoma in men less than 70 years old. J Urol. 1991;146:96-8.
10. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localised prostatic carcinoma. Brit J Urol. 1992,69:183-7.
11. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-6.
12. Egawa S, Go M, Kuwao S, Shoji K, Uchida T, Koshiba K. Long-term impact of conservative management on localized prostate cancer. A twenty-year experience in Japan. Urology. 1993;42:520-6.
13. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993;2:487-93.
14. Steineck G, Adolfsson J, Whitmore WF Jr. Local recurrence and disease-free survival. Doubtful parameters when comparing non-randomized studies of prostate cancer. Scand J Urol Nephrol Suppl. 1991;138:121-6.
15. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters [Editorial]. Ann Intern Med. 1993;119:948-9.
16. Adolfsson J, Steineck G, Whitmore WF Jr. Recent results of management of palpable clinically localized prostate cancer. Cancer. 1993;72:310-22.
17. Catalona WJ. Treatment strategies for prostate cancer [Letter]. JAMA. 1993;270:1691.
18. Johansson JE. Watchful waiting for early stage prostate cancer [Editorial]. Urology. 1994;43:138-42.
19. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-31.
20. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-8.
21. Aus G. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment. Scand J Urol Nephrol Suppl. 1994;167:1-41.
22. Thompson IM. Observation alone in the management of localized prostate cancer: the natural history of untreated disease. Urology. 1994;43(Suppl 2):41-6.
23. Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinorna of the prostate. J Urol. 1982;128:502-4.
24. Walsh PC, Lepor H. The role of radical prostatectomy in the management of prostatic cancer. Cancer. 1987;60(Suppl 3):526-37.
25. Hanks GE. External-beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monogr. 1988;7:75-84.
26. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys. 1988;15:1307-16.
27. Hanks GE, Krall JM, Hanlon AL, Asbell SO, Pilepich MV, Owen JB. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys. 1994;28:39-45.
28. Kaplan ID, Cox RS, Bagshaw MA. Radiotherapy for prostate cancer: patient selection and the impact of local control. Urology. 1994;43:634-9.
29. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Follow-up cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996;88:116-73.
30. Stein A, deKernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 1992;147(3 Pt 2):942-6.
31. Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, et al. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol. 1994;12:2254-63.
32. Kantoff PW, Talcott JA. The radical prostatectomy series: apples are not oranges. J Clin Oncol. 1994;12:2243-5.
33. Byar DP, Corle DK. VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer. Veterans Administration Cooperative Urological Research Group. Urology. 1981;17(4 Suppl):7-11.
34. Graversen PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stage I and II prostatic cancer. A fifteen-year follow-up. Urology. 1990;36:493-8.
35. Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology. 1993;42:622-9.
36. Mark DH. Mortality of patients after radical prostatectomy: analysis of recent Medicare claims. J Urol. 1994;152:896-8.
37. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129-35.
38. Fowler FJ Jr, Barry MJ, Lu-Yao GL, Wasson J, Roman A, Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology. 1995;45:1007-15.
39. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS, et al. Screening for prostate cancer. A decision analytic view, JAMA. 1994;272:773-80.
40. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993;269:2650-8.
41. Beck JR, Kattan MW, Miles BJ. A critique of the decision analysis for clinically localized prostate cancer. J Urol. 1994;152(5 Pt 2):1894-9.
42. Simpson KN, Brown RE. Cost effectiveness of adding a prostate specific antigen test to digital rectal examination for early detection of prostate cancer [Abstract]. J Urol. 1993;149:413A.
43. Littrup PJ, Goodman AC, Mettlin CJ. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. CA Cancer J Clin. 1993;43:134-49.
44. Mold JW, Holtgrave DR, Bisonni RS, Marley DS, Wright RA, Spann SJ. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis. J Fam Pract. 1992;34:561-8.
45. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990;17:719-37.
46. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-23.
47. Love RR, Fryback DG, Kimbrough SR. A cost-effectiveness analysis of screening for carcinoma of the prostate by digital examination. Med Decis Making. 1985;5:263-78.
48. Richte JP. Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology. 1993;42:365-74.
49. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or BO) prostate cancer. Pathologically significant tumors. Urol Clin North Am. 1993;20:687-93.
50. Aus G, Hermansson CG, Hugosson J, Pedersen KV. Transrectal ultrasound examination of the prostate: complications and acceptance by patients. Br J Urol. 1993;71:457-9.
51. Collins GN, Lloyd SN, Hehir M, McKelvie GB. Multiple transrectal ultrasound-guided prostatic biopsies - true morbidity and patient acceptance. Br J Ural. 1993;71:460-3.
52. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146-54.
53. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633-6.
54. National Center for Health Statistics. Volume 2: Mortality part A. In: Vital Statistics of the United States, 1986. Washington, DC: U.S. Department of Health and Human Services; 1986; DHHS publication no. (PHS) 86-1101.
55. Barry MJ, Fleming C Coley CM, Wasson JH, Fahs MC, Oesterling JE. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? IV. Estimating the risks and benefits of an early detection program. Urology. 1995;46:445-61.
56. Epstein JI, Carmichael MJ, Pizov G, Walsh PC Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol. 1993;150:135-41.
57. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multi-center clinical trial of 6,630 men. J Urol, 1994;151:1283-90.
58. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-74.
59. Brendler CB, Carmichael M, Walsh PC, Epstein JI. Radical prostatectomy (RP) for non-palpable prostate cancer diagnosed by needle biopsy: pathologic and clinical findings. J Urol. 1993;149:378A.
60. U.S. Congress, Office of Technology Assessment. Cost and Effectiveness of Prostate Cancer Screening in Elderly Men. Washington, DC: US Gov Pr Off; 1995.
61. Riley G, Lubitz J, Prihoda R, Rabey E. The use and costs of Medicare services by cause of death. Inquiry. 1987;24:233-44.
62. Tengs TO, Adams ME, Pliskin JS, Safran OG, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis. 1995;15:369-90.
63. Walsh PC. Prostate cancer kills: strategy to reduce deaths. Urology. 1994;44:463-6.
64. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin. 1993;43:42-6.
65. Schroder FH. Prostate cancer: to screen or not to screen? [Editorial] BMJ. 1993;306:407-8.
66. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet. 1994;343:958-60.
67. Sox HC Jr. Preventive health services in adults. N Engl J Med. 1994;330:1589-95.
68. Screening for Prostate Cancer: commentary on the recommendations of the Canadian Task Force on the Periodic Health Examination. The U.S. Preventive Services Task Force. Am J Prev Med. 1994;10:187-93.
69. Jonler M, Messing EM, Rhodes PR, Bruskewitz RC. Sequelae of radical prostatectomy. Br J Urol. 1994;74:352-8.
70. U.S. Preventive Services Task Force. Screening for colorectal cancer. In: U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2d ed. Baltimore: Williams & Wilkins; 1996: 89-103.
71. Lee JM. Screening and informed consent. N Engl J Med. 1993;328:438-40.
72. Marshall KG. Screening for prostate cancer. How can patients give informed consent? Can Fam Physician. 1993;39:2385-90.
73. Hahn DL, Roberts RG. PSA screening for asymptomatic prostate cancer: truth in advertising [Editorial]. J Fam Pract. 1993;37:432-6.
74. Flood AB, Wennberg JE, Nease RF Jr, Fowler FJ Jr, Ding J, Hynes LM. The importance of patient preferences in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med. 1996;11:342-9.